PCT Strategy for Chinese Applicants: Maximizing Value at the National Phase

Chinese applicants file more PCT applications than any other country — but the strategic opportunities built into the PCT framework remain systematically underutilized. The 30-month window between international filing and national phase entry is not simply a delay — it is an opportunity to reshape claim strategy based on information that was unavailable at filing.

Reading the ISR as a Strategic Document

The International Search Report (ISR) and accompanying Written Opinion (WO) represent the International Searching Authority's (ISA) preliminary assessment of novelty and inventive step. Most applicants receive the ISR, note whether the claims received an "A" category (novel) or "X/Y" category (novelty/inventive step issues), and simply proceed with national phase entry using the same claims.

This is a missed opportunity. The ISR tells you, in advance of national phase, which prior art the examiner found most relevant, which claim elements were considered distinguishing, and which independent claims are most at risk. A competent PCT strategy review uses this information to make three types of decisions:

Pre-national phase amendments: File Article 34 amendments (in Chapter II) or Rule 161 amendments (at EP) to address identified prior art before local prosecution begins
Selective national phase entry: Evaluate which jurisdictions justify the cost of entry given the strength of the claims and the commercial landscape in each market
Claim differentiation strategy: Identify how independent and dependent claims can be restructured to preserve maximum useful scope in each target jurisdiction, given different claim-drafting conventions at USPTO vs. EPO

ISA Selection for Chinese Applicants

Chinese applicants can designate CNIPA, the EPO, or other ISAs for the international search. The choice matters: EPO ISA searches tend to be broader and more thorough, particularly for NPL. A strong EPO ISA opinion — even a negative one — provides better prosecution intelligence than a permissive CNIPA ISA opinion that leaves prior art undiscovered until US or EP examination.

Chapter II and the IPRP

Chapter II Demand (request for International Preliminary Examination) is available to any PCT applicant but is elected by fewer than 10% of Chinese applicants. The result is an International Preliminary Report on Patentability (IPRP, Chapter II), which represents the IPEA's (International Preliminary Examining Authority's) view of patentability following dialogue with the applicant.

Chapter II is most valuable when the Written Opinion identifies prior art that can be overcome with targeted claim amendments, and when the applicant wants a favorable IPRP to carry into multiple national phase jurisdictions simultaneously. A positive IPRP does not bind national offices — they conduct independent examination — but it can accelerate examination in some jurisdictions and establishes a documented record that examiners may find persuasive.

Chapter II is generally not worth electing when the prior art identified in the Written Opinion presents fundamental patentability challenges that require substantial claim restructuring rather than targeted amendment, or when the only target jurisdictions are the US and EP (which conduct fully independent, thorough examination regardless of the IPRP).

Rule 161 / Rule 162 Amendments at the EPO: A Window Most Applicants Miss

This is one of the most underutilized tools available to PCT applicants entering the European phase. Under the EPO's Rules 161 and 162, PCT applicants entering the European national phase receive a six-month window — beginning with the EPO's notification under Rule 161 — during which they may file voluntary amendments to the claims and description without any examiner objection triggering the process.

National Phase Entry (31 months from priority)

Application enters EPO. Regional phase fees paid, translation filed if required.

EPO Issues Rule 161 Notification (~2–4 months)

EPO invites applicant to respond to the international written opinion. Six-month reply period begins.

Voluntary Amendment Window (~6 months)

Applicant may amend claims and description to address written opinion issues — without losing claim scope through examiner-driven prosecution. File Art. 123(2) EPC-compliant amendments that pre-empt anticipated objections.

Examination Begins

EPO examiner issues European Search Report (if not already issued) and first communication. Prosecution now begins on the applicant's preferred claim footing.

The strategic value of the Rule 161 window is that amendments filed during this period are proactive — not reactive. Reactive amendments (filed in response to an examiner's objection) create prosecution history that narrows claim scope and can estop the applicant from asserting certain equivalents. Proactive amendments, filed before any examiner communication, do not create the same prosecution history baggage.

US National Phase: A Different Set of Tools

At the US national phase (§ 371 entry), the corresponding voluntary amendment mechanism is a preliminary amendment filed with or shortly after the national phase entry documents. Unlike the EPO Rule 161 window, US preliminary amendments are filed at the applicant's initiative — there is no formal invitation from USPTO.

A preliminary amendment filed before the application enters the examination queue can restructure claims to address ISR prior art, add new dependent claims directed at commercially relevant embodiments, and adjust claim language to conform to USPTO prosecution conventions (addressing potential § 112 issues in the translated/adapted specification). No prosecution history estoppel attaches to preliminary amendments filed before the first Office action.

The 30 months between PCT filing and national phase entry are not simply a grace period for deferring prosecution costs. They are a window for building a prosecution strategy informed by international search results — using proactive amendment tools that preserve claim scope better than reactive prosecution.

Selective National Phase Entry: The Portfolio Triage Decision

For large Chinese PCT filers — enterprises with dozens or hundreds of PCT applications entering national phase simultaneously — not every application justifies the cost of full prosecution in every designated jurisdiction. The ISR and Written Opinion provide sufficient information to triage the portfolio before national phase entry fees are paid.

The evaluation framework should consider three factors per jurisdiction:

Claim strength: What is the realistic scope of claims likely to grant, given the prior art identified in the ISR? Is the granted claim commercially useful at that scope?
Market relevance: Is the product or technology covered by this application being commercialized or licensed in this jurisdiction? Is there realistic infringement to enforce against?
Cost-to-value ratio: USPTO prosecution to grant costs $15,000–$30,000+ across the entire lifecycle. EP prosecution is comparable. For applications where both factors above are marginal, national phase entry may not be the optimal deployment of prosecution budget.

Conclusion

The PCT framework is a sophisticated tool. Chinese applicants who use it only as a cost-deferral mechanism — filing PCT, waiting 30 months, then entering national phase with unchanged claims — are extracting a fraction of its strategic value. The ISR, the Chapter II examination option, the Rule 161 window at EPO, and the preliminary amendment opportunity at USPTO collectively offer a structured pathway to arrive at national phase with claims that have been informed by real search results and adapted to each jurisdiction's prosecution environment. This takes resources and expertise. It also produces better patents.